January 6th 2024, 3:00pm
An expert stressed the importance of finding a patient support group and asking questions after being diagnosed with kidney — or any other form — of cancer.
January 5th 2024, 1:30pm
Response is assessed in patients starting a JAK inhibitor by monitoring symptoms on a severity scale, spleen size, blood counts, and overall patient impression of change, with the goal being reduction of symptoms and stabilization of blood counts to improve quality of life.
January 5th 2024, 1:00pm
The JAK inhibitors approved for myelofibrosis have common side effects of cytopenias and gastrointestinal issues, with additional risks of weight gain and cardiac effects and diarrhea; momelotinib and pacritinib show improved tolerability compared to earlier JAK inhibitors.
December 29th 2023, 1:30pm
An expert discusses the four FDA-approved JAK inhibitors for myelofibrosis - ruxolitinib, fedratinib, pacritinib, and momelotinib.
December 29th 2023, 1:00pm
Christine Cooper, RN, BSN, explains anemia in myelofibrosis is managed by stimulating red blood cell production with medications, transfusions, and newer therapies that may stabilize red cell counts.
December 28th 2023, 2:00pm
A doctor reflected on what it was like treating patients with myeloproliferative neoplasms years ago and how much treatments have improved.
December 27th 2023, 2:00pm
An expert explained the benefits of patients with myeloproliferative neoplasms finding a community of people with similar diagnoses.
December 26th 2023, 2:00pm
New treatments and ongoing trials are providing more options and better outcomes for patients with myeloproliferative neoplasms, an expert explained.
December 25th 2023, 2:00pm
After being diagnosed with essential thrombocythemia, Marilyn Kay Edwards was not told much about her disease.
December 24th 2023, 2:00pm
When caring for his wife with myelofibrosis, Ed Bartholemy focused on making her life as fun and positive as possible, despite her limitations.
Advocacy and ‘Radiating Valor’ Have a Transformative Impact
Air Matters: Radon and the Environment
Odronextamab Elicits Responses in Some With Lymphoma Following CAR-T
LCI Launches Screening Saves Program